Status:
UNKNOWN
When to Apply to Which Patient in MSC?
Lead Sponsor:
Trabzon Kanuni Education and Research Hospital
Conditions:
COVID-19 Acute Respiratory Distress Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
Mesenchymal stem cell (MSC) therapy is among the promising treatments for acute respiratory distress syndrome (ARDS). Our study aimed to investigate the clinical efficacy of MSC treatment in COVID-19 ...
Detailed Description
The study was conducted retrospectively in patients diagnosis of COVID-19 in the intensive care units. Patients with severe ARDS \[partial pressure of arterial blood oxygen and inhaled oxygen fraction...
Eligibility Criteria
Inclusion
- Patients who were followed up and treated after being admitted to the Intensive Care Unit after March 2020
- Patients with COVID PCR +
- Typical or suspected cases of Thorax BT COVID
- Cases over the age of 18.
Exclusion
- Those with a contraindicated condition (cancer disease, allergy) for MSC application
- Those who are endotracheal intubated during the application and are connected to a respirator
- Those who died in the first 24 hours after the application
- Cases that are not positive or suspicious for COVID.
- Cases under the age of 18.
- Cases where patient data could not be reached.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2022
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT05240430
Start Date
January 1 2022
End Date
March 31 2022
Last Update
February 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Trabzon Kanuni Training and Research Hospital, University of Healthy Sciences
Trabzon, Yomra, Turkey (Türkiye), 61500